Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery.
Neurologia
; 30(3): 163-8, 2015 Apr.
Article
in En, Es
| MEDLINE
| ID: mdl-24468659
ABSTRACT
OBJECTIVE:
This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain. MATERIAL ANDMETHODS:
Cost-effectiveness ratios were determined in terms of incremental cost per complete resection (CR) and incremental cost per additional quality-adjusted life year (QALY), based on data collected in the VISIONA observational study.RESULTS:
Incremental cost with 5-ALA versus conventional surgery using white light only amounts to 4550 per additional CR achieved and 9021 per QALY gained. A sensitivity analysis shows these results to be robust.CONCLUSION:
Malignant glioma surgery guided by 5-ALA fluorescence entails a moderate increase in hospital costs compared to current surgical practice and can be considered a cost-effective innovation.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Cost-Benefit Analysis
/
Fluorescence
/
Glioma
/
Aminolevulinic Acid
Type of study:
Health_economic_evaluation
/
Observational_studies
Limits:
Adult
/
Aged
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
/
Es
Year:
2015
Type:
Article